FORMA Therapeutics Appoints Chris Kirby to General Counsel

WATERTOWN, Mass.--(BUSINESS WIRE)--FORMA Therapeutics announced today that Christopher Kirby, J.D., MPH has been appointed to the position of General Counsel. Mr. Kirby was most recently Vice President and Global Head Legal, Biosurgery and Renal Divisions, for Sanofi in Cambridge, Mass.

"Chris is an experienced corporate lawyer and business professional who provided global oversight of legal services to corporate divisions marketing a dozen patient-tailored products, making him an ideal fit as we build FORMA into an integrated pharmaceutical company," said Steven Tregay, President and CEO of FORMA Therapeutics. "In his previous role, Chris has advised senior management on strategic business objectives, clinical development and commercial launch readiness, personalized medicine initiatives, and compliance and training standards, activities that align with FORMA's growth trajectory."

"It is a privilege to join such a dynamic biotechnology firm with a foundation built on innovative science, a patient-centric focus, and adaptable business structures," said Chris Kirby. "I look forward to joining FORMA and contributing my background and expertise in the role of General Counsel."

Prior to joining Sanofi (formerly Genzyme Corporation), Mr. Kirby practiced law at Ropes & Gray LLP, where he advised private equity sponsors, biotechnology companies, academic medical centers and other health care providers on a broad range of corporate matters and financing transactions. Mr. Kirby received his B.A. cum laude from the University of Pennsylvania, his J.D. with honors from The George Washington University Law School, and his MPH from the George Washington University School of Public Health and Health Services.


FORMA Therapeutics targets essential cancer pathways to create transformative small molecule cancer therapies. FORMA's novel approach to accessing high value drug targets, many of which pose significant challenges to conventional discovery approaches, leverages the integration of its innovative drug discovery technologies and oncology expertise, enabling efficient screening, discovery and rational development of small molecule drug candidates with qualified cellular mechanisms of action. FORMA is leveraging translational and clinical development capabilities through their strategic relationship with Dr. Daniel Von Hoff and Translational Drug Development (TD2) to build a robust pipeline of transformative cancer therapies in areas such as tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. FORMA is headquartered in Watertown, MA.


For FORMA Therapeutics
MacDougall Biomedical Communications
Kari Watson or Charles Liles, +1 781-235-3060
[email protected] or [email protected]